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Abstract
Background: The development of an effective AIDS vaccine has been a formidable task, but remains a critical
necessity. The well conserved membrane-proximal external region (MPER) of the HIV-1 gp41 glycoprotein is one of
the crucial targets for AIDS vaccine development, as it has the necessary attribute of being able to elicit antibodies
capable of neutralizing diverse isolates of HIV.
Methodology/Principle Findings: Guided by X-ray crystallography, molecular modeling, combinatorial chemistry,
and powerful selection techniques, we designed and produced six combinatorial libraries of chimeric human
rhinoviruses (HRV) displaying the MPER epitopes corresponding to mAbs 2F5, 4E10, and/or Z13e1, connected to an
immunogenic surface loop of HRV via linkers of varying lengths and sequences. Not all libraries led to viable chimeric
viruses with the desired sequences, but the combinatorial approach allowed us to examine large numbers of MPER-
displaying chimeras. Among the chimeras were five that elicited antibodies capable of significantly neutralizing HIV-1
pseudoviruses from at least three subtypes, in one case leading to neutralization of 10 pseudoviruses from all six
subtypes tested.
Conclusions: Optimization of these chimeras or closely related chimeras could conceivably lead to useful
components of an effective AIDS vaccine. While the MPER of HIV may not be immunodominant in natural infection
by HIV-1, its presence in a vaccine cocktail could provide critical breadth of protection.
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Introduction
Despite the continued absence of an AIDS vaccine, it is
widely agreed that a vaccine must be developed, as it is the
most promising strategy for widespread protection against
AIDS. The consensus has been that an ideal prophylactic AIDS
vaccine will target the earliest events of infection by human
immunodeficiency virus (HIV) and activate both the humoral
and cellular immune responses [1,2,3] with an emphasis on
eliciting broadly neutralizing antibodies, since B-cell responses
are likely to confer the greatest long-term protection [4,5,6]. In
support of this, passive administration of neutralizing antibodies
has provided protection in nonhuman primates challenged with
simian HIV (SHIV) [7,8,9,10,11] and has been associated with
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e72205
measurable benefits in controlling viremia in HIV-1-infected
humans [12]. Furthermore, immunization studies with various
envelope-based constructs have shown immune protection in
macaques [13,14,15,16,17] as well as 31.2% efficacy in
humans (in the RV144 phase III clinical trial, involving a
recombinant viral vector prime followed by an envelope protein
boost [18]), offering early glimmerings for hope that improved
immunogens might offer greater protection.
The greatest challenge to AIDS vaccine development has
been the inability to isolate or engineer safe and broadly
neutralizing immunogens that can block infection by the diverse
circulating strains of HIV. Efforts to generate the necessary
breadth of protection have focused, in large part, on the highly
conserved membrane proximal external region (MPER) of
gp41. Among the roughly 20 broadly neutralizing antibodies
(bnAbs) known to target the envelope glycoproteins gp120 and
gp41 [19,20,21], broadly neutralizing antibodies 2F5, 4E10,
Z13e1, and more recently, 10E8 target the MPER.
Studies with the 2F5, 4E10, Z13e1, and 10E8 mAbs have
helped elucidate the dynamic movement that the MPER
normally undergoes in the processes of membrane fusion and
viral entry [22,23,24,25,26,27,28,29,30,31]. By bending the
MPER at a hinge (2F5, 4E10, and 10E8) or rigidifying the
structure of the MPER (Z13e1) [26,27,28,29,31], the MPER-
directed antibodies appear to effect neutralization by interfering
with the post-CD4 binding steps necessary for formation of the
pre-hairpin intermediate [32], most likely via a required initial
interaction of their H3 loops with the viral membrane [26,33,34].
Efforts to generate MPER-based immunogens have been
particularly challenging, with most efforts yielding little or no
neutralization [15,35,36]. More recently, Wang et al. [37]
described constructs in which the N- and C-terminal heptad
repeats of HIV gp41 were connected via linkers to form six-
helix bundles with C-terminal MPER tails. These constructs
were able to neutralize primary pseudovirus infection and
inhibit syncytium formation and cell-to-cell transmission of
virus, but this ability required large doses of purified IgGs.
Likewise, Zhou et al. [38] described peptide conjugates
encompassing the 2F5 epitope and part of the 4E10 epitope
that were able to elicit modest neutralization against Tier 1 HIV
isolate SF162.SL. More promising was a report [39] describing
the production of chimeric influenza: HIV constructs (in which
HIV gp120 was replaced with influenza hemagglutinin (HA),
leading to gp41: HA chimeras, some of which were presented
on SIVmac239 Gag virus-like particles. One chimera was able
to elicit neutralizing antisera in guinea pigs capable of
neutralizing three Tier 2 subtype B pseudoviruses.
In this work, we modeled the 2F5 and 4E10 epitopes into a
surface loop of human rhinovirus type 14 (HRV14) in silico with
the goal of minimizing the need for significant conformational
reorganization upon binding partner mAbs 2F5 and 4E10.
Graphic models were used to design combinatorial libraries in
which the epitopes were connected to the HRV loop by short
linkers of variable lengths and sequences, optimized to include
HIV-like presentations of the epitopes (as has been done
previously to generate other immunogenic presentations of HIV
epitopes [35,40,41,42]). In the case of the 2F5 epitope
presentations, we previously explored novel molecular
dynamics simulations approaches that optimized the length,
hydrophobicity, and propensity of the epitope for vaccine
design [43] aiming to promote the HIV-like type 1 β-turn
conformation of this epitope [44]. In the case of the 4E10
epitope, we aimed to promote the known amphipathic α-helical
structure of this epitope in its free and antibody-bound
conformations. Once generated, the chimeric viruses were
subjected to immunoselection protocols using the cognate HIV
antibodies to identify the viruses most optimally displaying the
inserted epitope. To assess the antigenicity of a guided
sampling of the viruses, we used direct and competitive
ELISAs (measuring the ability of HIV MPER antibody to bind
the MPER-presenting chimeras) as well as a neutralization
assay (measuring the ability of HIV MPER antibody to inhibit
MPER-presenting chimeric virus infection of cells). After
assessing the antigenicity, those deemed to present their HIV
epitopes in ways well recognized by 2F5 or 4E10 were chosen
to immunize guinea pigs.
One of the chimeras displaying the 2F5 epitope was able to
elicit neutralizing responses against pseudoviruses of the AE,
F, and, to a lesser extent, D subtypes. Among 10 chimeras
designed to display the 4E10 epitope, one elicited neutralizing
antibody responses against pseudoviruses of subtypes A, B, C,
D, AE, and F (representing all of the subtypes tested) while
four others elicited significantly neutralizing antibodies against
pseudoviruses of the AE, F, and, to a lesser extent, A, B, or D
subytpes. While the neutralization titers obtained were modest,
this work confirms that HRV chimeras displaying MPER
sequences can induce broad anti-HIV-1 neutralizing
responses, and could possibly be further optimized to elicit
more potent immune responses.
Materials and Methods
Cells, viruses, media, bacteria and plasmids
H1-HeLa cells [45] were used to produce, propagate, titer,
and immunoselect wild-type HRV14 as well as the recombinant
HRV14: HIV-1 gp41 2F5 and 4E10 chimeric viruses. M medium
[46] with 1-10% fetal bovine serum was used for propagation of
the viruses; PA medium [46] with 1-10% fetal bovine serum
was used for isolation and titering of the viruses; Dulbecco’s
modified Eagle medium (DMEM; Gibco, BRL, Carlsbad, CA)
was used for HeLa cell transfection; and AH medium [46] was
used for large-scale propagations of the viruses. The bacterial
strain used for transformation of the engineered plasmids was
E. coli DH10B ElectroMax (Gibco, BRL, Carlsbad, CA). The
pST-LIC plasmid was used for all of the genetic engineering.
This plasmid was derived from modification of the previously
used HRV-encoding p3IIST plasmid [47], whereby the
sequences flanking the missing VP2 puff of the NIm-II region of
HRV14 [48] were modified to have extended sticky ends to
maximize the efficiency of ligation with complementary HIV-
encoding DNA oligonucleotides [42].
Antibodies and peptides
The broadly neutralizing human mAbs, 2F5 (PolyMun, Inc.,
Vienna, Austria), which binds the gp41 MPER epitope
E662LDKWA667 [49], 4E10 (PolyMun, Inc., Vienna, Austria),
Cold Viruses Displaying HIV-1 gp41 Immunogens
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which binds the gp41 MPER epitope, N671WFDITNW678, and
Z13e1 (Michael Zwick, The Scripps Research Institute, La
Jolla, CA), which binds to the gp41 MPER epitope,
N671WFDIT676, were used for immunoselections and, in the
case of 2F5 and 4E10, antigenicity assays. Antibodies used for
ELISAs included anti-HRV14 murine mAbs 1 and 17 [which
bind to the neutralizing immunogenic site IA (NIm-IA) [50] and
were provided by Dr. Roland Rueckert, University of
Wisconsin, Madison, WI], horseradish peroxidase (HRP)-
conjugated goat-anti-mouse IgG (Cappel ICN, Irvine, CA), and
Fc-specific sheep anti-mouse IgG (Sigma, St. Louis, MO). Ac-
EQELLELDKWASLW-NH2 peptide (synthesized by NeoMPS,
Inc., San Diego, CA) and the K7-D11 lactam-bridged Ac-
NWFDITK 7WLWD 11KKK-NH2 (NK-15) peptide, (purchased
from Chempep, Inc., Wellington, FL but originally synthesized
and characterized by Michel Sun in the laboratory of Dr. John
W. Taylor, Department of Chemistry and Chemical Biology at
Rutgers University) were employed for competition in ELISAs
and for elution of the chimeric viruses in competitive
immunoselections. Three keyhole limpet hemocyanin (KLH)-
conjugated peptides were used for immunization of guinea
pigs: KLH-EQELLELDKWASSLW-NH2 (KLH-P-E; NeoMPS,
Inc., San Diego, CA), KLH-EQELLALDKWASSLW-NH2 (KLH-
P-A; NeoMPS, Inc., San Diego, CA), and KLH-C‑NWFDITK
7WLWD 11KKK-NH2 (KLH-NK-15; Chempep, Inc., Wellington,
FL).
Production of the chimeric HRV14: ELDKWA (2F5) and
HRV14: NWFDITKWLW (4E10) libraries
The libraries produced for this work are shown in Figure 1.
For each combinatorial library, a complex set of
complementary recombinant DNA oligonucleotides was
synthesized (all by IDT, Piscataway, NJ). The oligomers were
designed to overlap in the epitope-encoding region using
codons preferred by the HRV14 RNA polymerase. Sets of
complementary epitope-encoding DNA oligonucleotides were
hybridized together and extended to fill in the variable-
sequence overhangs on both ends [using each of the dNTPs
and Klenow DNA polymerase I (New England Biolabs, Beverly,
MA)]. The resultant double-stranded cassettes were then
treated with bacteriophage T4 DNA polymerase (Sigma, St.
Louis, MO) and dGTP to generate the complementary 11-15
base sticky ends due to the 3’–5’ exonuclease activity of the T4
DNA polymerase in the presence of dGTP. The HRV14-
encoding pST-LIC plasmid was uniquely digested in the region
for insertion with BseRI and then treated with T4 DNA
polymerase and dCTP to generate long complementary sticky
ends. A ligation-independent cloning method was used in
which the sticky-ended ELDKWA-encoding oligonucleotides
were hybridized to the sticky-ended vector in a 10:1 ratio at
22°C for 1 h. The recombinant plasmids were amplified by their
electroporation into DH10B E. coli cells using a Gene Pulser
system (Bio-Rad laboratories, Hercules, CA) at 1.8 kV, 200
ohms, and 25 µF in 0.1 cm pre-chilled cuvettes). Transformed
cells were grown in bulk liquid cultures at 30-37°C to late log
phase and then harvested using HiSpeed Mini- or Midi-Prep
Spin Kits (Qiagen, Valencia, CA). After purifying and linearizing
the pools of recombinant plasmids with MluI, the plasmids were
transcribed in vitro using Ambion MegaScript kits (Austin, TX).
Full-length RNA transcripts were transfected into H1-HeLa cells
by electroporation (using 10 µg/10 µL of the infectious RNAs
added to 1 X 107 H1-HeLa cells in 400 µL of D-MEM in 0.4 cm
Gibco-BRL electroporation cuvettes [using a Gene Pulser
system (Bio-Rad laboratories, Hercules, CA) at 250 V, and 950
µF]. The resultant chimeric viruses were grown by plating the
transfected cells with an equal number of unpulsed cells for
virus propagation, incubating at 34.5°C for 3-4 days, and
harvesting when the cytopathic effect (CPE) reached
approximately 90% as previously described [46].
Partial purification of virus libraries and virus isolates
A protocol developed by Zhang et al. [51] was followed for
the partial purification (“mini purification”) of the combinatorial
virus libraries as well as for individual viruses. Briefly, after
three cycles of freezing and thawing, the concentrated
harvested suspensions of infected cells were centrifuged (to
remove cell wall debris), after which the clarified lysates were
subjected to DNase I treatment followed by ultracentrifugation
(with a 30% sucrose cushion) at 42,000 rpm for 2.5 h at 15°C
in a Beckman 45 Ti rotor. The pellets, which contained the
chimeric viruses as well as some cell-derived ribosomes, were
resuspended in 20 mM Tris-HCl, pH 7.4 (sometimes with
100-150 mM NaCl added to improve solubilization).
Immunoselection of viruses
Immunoselection was performed as previously described
[35,47] with some modifications. Ninety-six-well Immunosorp
plates (Nunc, Rochester, NY) were coated with mAb 2F5
(using a 10 nM solution) or 4E10 (using a 0.84, 6.7, or 13.3 nM
solution) to capture chimeric rhinovirus pools with
conformations well recognized by the mAb, essentially as
described previously [41]. After overnight incubation at 4°C,
plates were blocked with 3% gelatin in phosphate-buffered
saline (PBS) or 4% nonfat dry milk in PBS for 1 h at 37°C.
Without peptide competition.  Plates were washed six
times with PBS/0.05%-0.1% Tween 20 (PBS-T) and 3 X 105
plaque-forming units (PFU)/well of chimeric viruses were added
and incubated for 2 h at 34.5°C and 2.5% CO2. Plates were
washed five times with PBS-T and three times with PBS only.
Antibody-bound virus was eluted either with H1-HeLa cells
alone or with peptide followed by cells. When peptide was used
(as was the case with some of the 4E10 sub-libraries), 750 to
3000 µM of NK-15 was used in the first rounds and 750-6000
µM in the 2nd round of immunoselection (incubated for 2 h at
37°C, then washed six times with 0.1% PBS-T). In the absence
of peptide-induced release of chimeras and in the cases
following peptide-induced release, 2 X 104 H1-HeLa cells were
seeded into the wells using medium M with 10% FBS per well.
Plates were then incubated at 34.5°C, 2.5% CO2 for up to 72 h
(until cells reached 80-<100% CPE). The harvested cells were
lysed by three cycles of freezing and thawing and then
centrifuged to produce clarified virus lysates.
With peptide competition
Competitive immunoselection was performed like
immunoselection without peptide competition, with one
Cold Viruses Displaying HIV-1 gp41 Immunogens
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modification. Prior to the addition of virus to the antibody-
coated plates, virus was preincubated for 1 h at room
temperature with peptide. In the case of the 2F5 libraries, 0, 2,
4, 8, and 16 nM of competitive peptide Ac-
EQELLELDKWASSLW-NH2 were used; in the case of the 4E10
libraries, 0-320 nM of competitive peptide NK-15 was used in
the first round and 0-640 nM in the 2nd round of
immunoselection.
Enzyme-linked immunosorbent assays (ELISAs) of
library pools and chimeric viruses
Direct ELISAs.  Direct enzyme-linked immunosorbent
assays (ELISAs) were performed in triplicate on individual
viruses and virus pools to assess virus binding to 4E10
antibody. In brief, 96-well Maxisorp plates (Nunc, Denmark)
were coated with 0.2 µg/well of 4E10 monoclonal antibody in
50 mM sodium borate, pH 8.5 at 4°C overnight, and then
blocked with 4% non-fat dry milk in phosphate-buffered solution
(PBS) for 1 h at 37°C. After washing the plates six times with
PBS/0.1% Tween 20 (PBS-T), serially diluted chimeric viruses
or virus pools were added into the wells and incubated for 2 h
at 37°C. Plates were washed and 0.4 to 1.3 µg/ml of anti-
HRV14 mAb 1 was added, incubated for 1 h at 37°C, washed
six times, and treated with HRP-conjugated sheep anti-mouse
IgG. Then, peroxidase substrate (0.3 mg/ml
tetramethylbenzidine dissolved in 10% dimethyl sulfoxide in
Figure 1.  Design of 2F5- and 4E10 libraries produced in effort to obtain useful HIV-1 MPER-displaying immunogens.  X =
any of the 20 amino acids. B’s indicate biasing of residues (to represent mixtures of the HIV-1 residues found at the given site (in
proportion to their representation in the Los Alamos Database) with randomized residues (X) to allow for other solutions that would
be compatible with virus viability and optimal presentation of the epitope. One exception to using the HIV residues in the mixture is
the use of an equimolar mixture of D/A/E in Library III; this was chosen in the 4E10 Lib III to promote α-helix formation. Subscripts
correspond to relative percentages encoded (in the case of the HIV residue, reflecting the values among HIV-1 isolates at the time
of the library designs).
doi: 10.1371/journal.pone.0072205.g001
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0.18 M sodium citrate, pH 3.95) was added. The reaction was
catalyzed by the addition of H2O2 to 0.009%, allowed to
develop color, and then stopped by the addition of an equal
volume of 1 M H2SO4. Titers are expressed as reciprocals of
virus stock dilutions (relative to an initial concentration of 1 X
108 PFU/ml) at which an optical density at 450 nm (OD450) of
0.5 was achieved. All data are reported as the average of three
measurements, with the errors shown as the standard errors of
the mean.
Competitive ELISAs.  Competitive ELISAs were performed
in triplicate using immobilized mAb 2F5 or 4E10 according to
Arnold et al. [35] with the exception that 3 X 105 PFU virus
were mixed with either the 14-mer ELDKWA-containing peptide
or the NK-15 peptide in serial dilutions before being added to
immobilized 2F5 or 4E10 for 2 h at 37°C. The anti-HRV14 mAb
17 was added, and the samples were incubated and then
washed prior to treatment with HRP-conjugated goat anti-
mouse IgG. The samples were further incubated, washed, and
treated with peroxidase substrate. The color reactions were
stopped and read as above. All data are reported as the
average of three measurements, with the errors shown as the
standard errors of the mean. The competing peptide was used
to promote more stringent binding of mAb to those chimeras
displaying the epitope in conformations better resembling those
of the native epitope than the peptide.
Chimeric virus MTT neutralization assay
Chimeric virus MTT neutralization assays were performed as
previously described [35,47]. Briefly, 50 µl of 2 X 105 PFU/ml of
chimeric viruses was incubated in M medium for 1 h at 34.5°C,
2.5% CO2 with 50 µl of sequential two-fold dilutions of mAb
(starting at a 4 µg/ml concentration) in 96-well tissue-culture
microtiter plates (Nunc, Rochester, NY. 50 µl of H1-HeLa cells
was added at a concentration of 2 X 105 cells/ml. The plates
were incubated at 34.5°C, 2.5% CO2 for up to 48 h. 15 µl of a 5
mg/ml solution of 3-(4,5 dimethylthiazol)-2-yl-2,5-
diphenyltetrazolium bromide (MTT; Sigma-Aldrich, St. Louis,
MO) in PBS was added to the wells. After a 1.5 h incubation at
34.5°C, 2.5% CO2, the reaction was stopped by adding 150 µl
of 20% sodium dodecyl sulfate in 50% N,N-dimethylformamide.
Cell survival was defined as the percentage of the OD570
observed compared to that of the cell control wells, which
displayed 100% viability. The antibody 50% inhibitory
concentration (IC50) values correspond to the mAb
concentration necessary to neutralize chimeric virus infection
by 50%. All data are reported as the average of three
measurements, with the errors shown as the standard errors of
the mean.
Plaque isolation and sequencing of chimeric viruses
Individual virus plaques were subjected to two rounds of
plaque purification according to Smith et al. [41]. The chimeric
viruses were then propagated in 60 mm dishes. Viral RNAs
were isolated using QIAamp Viral RNA Purification Kits
(Qiagen, Valencia, CA) and RT-PCR was performed using
QIAquick Gel Extraction Kits (Qiagen, Valencia, CA) on
electrophoresed PCR products. The DNA fragments were then
sequenced (IDT, Piscataway, NJ).
Transmission Electron Microscopy
The mini-purified chimeric viruses were diluted 100-fold with
100 mM Tris-HCl, pH 7.4. Formvar/Carbon grids were each
treated with a drop of virus solution and then stained with 1%
phosphotungstic acid for 5 minutes. The grids were washed 5
times with distilled water, air dried for 5 minutes, and then
observed using a JEOL 1200EX scanning/transmission
electron microscope.
Immunization of guinea pigs
Young male Dunkin Hartley guinea pigs were immunized
subcutaneously with each chosen chimeric virus (using three
guinea pigs/chimera). The immunizations were carried out as
follows: weeks 0 and 4: 40 µg (approximately 1 X 109 PFU) of
mini-purified chimeric virus in either 10 mM Tris-HCl or -HAc,
pH 7.4; for weeks 9 and 13: 40 µg of mini-purified chimeric
virus in 10 mM Tris-HCl or -HAc, pH 7.4 boosted with
corresponding keyhole limpet hemocyanin (KLH)-conjugated
peptide. (For the ELDKWA chimeras (B1 and C1), the peptide
boosts consisted of 80 µg each of KLH-EQELLELDKWASSLW-
NH2 (KLH-P-E) and KLH-EQELLALDKWASSLW-NH2 (KLH-P-
A), mixed with an equal volume of complete Freund’s adjuvant
(CFA) for week 9 and an equal volume of incomplete Freund’s
adjuvant (IFA) for week 13. For the NWFDITKWLW chimeras,
the peptide boosts consisted of 120 µg KLH-conjugated 16-mer
K8-D12 lactam-bridged peptide KLH-C-
NWFDITKWLWDKKKK-NH2 (KLH-NK-15) mixed with an equal
volume of CFA for week 9 and an equal volume of IFA for week
13. In all of the physiological solutions tested, the
NWFDITKWLW peptide was predominantly dimeric. Sera were
collected by femoral bleeds or heart sticks at weeks -1, 7, 12,
and 16.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Office of Laboratory Animal
Welfare (OLAW) and submitted in compliance with the Public
Health Service (PHS) Policy on Humane Care and Use of
Laboratory Animals (Identification Number: A3669-01). All
blood collections were performed with ketaset and xylazine,
and technicians were trained to minimize suffering by the
animals.
HIV-1 pseudovirus neutralization assay
We assessed the ability of the sera from chimera-immunized
guinea pigs to neutralize recombinant HIV-1 pseudoviruses of
diverse subtypes and co-receptor usages using a single-round
replication assay [52] developed at Monogram Biosciences,
Inc. (South San Francisco, CA). The pseudoviruses were
preincubated with various dilutions of heat-inactivated guinea
pig sera for 18 hours and then added to U87 cells expressing
the CD4 receptor and the CCR5 and CXCR4 co-receptors.
Neutralizing titers were calculated after one round of replication
as the reciprocal of the guinea pig serum dilution yielding 40%
Cold Viruses Displaying HIV-1 gp41 Immunogens
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inhibition of the reporter luciferase activity (compared with
pooled normal guinea pig serum values).
Results
Construction and production of three combinatorial
ELDKWA/2F5 libraries
2F5 Library I.  In an effort to produce live-virus immunogens
capable of eliciting effective and cross-reactive immune
responses against HIV-1, we have made a number of
combinatorial libraries of chimeric viruses that display the
conserved 2F5 epitope, E662LDKWA667 [49,53], of the HIV-1
membrane-proximal external region (MPER; [35,42]; and this
work). This region of the MPER appears to be flexible, normally
assuming an extended structure in the N-terminal portion and a
helical structure in the C-terminal portion, becoming more
extended with β-turn conformations in the presence of 2F5
[31,43,44,54,55,56,57]. The extension of the ELDKWA
residues appears to be initiated by the binding of the CDR H3
loop of 2F5 to the adjacent 4E10 epitope in the vicinity of
residues 669-672 [27,29,31,58], lifting L669 and W670 out of
the membrane [29].
In previous work [42], we produced a subset of a
combinatorial library for which the design was enhanced by
molecular modeling, using simulations that illustrated the
importance of optimizing such key features as the length,
hydrophobicity, and conformational propensity of the ELDKWA
sequence that was to be inserted in the VP2 puff [59], the
major loop of neutralizing immunogenic site II of HRV14
[50,60]. Given that numerous ELDKWA peptides bound to 2F5
are characterized by having a predominant type 1 β turn [44],
our goal was to produce a type 1 β-turn conformation upon
inserting the ELKDWA epitope onto the surface of HRV14. We
assumed that predisposing the ELDKWA epitope to bind to 2F5
would translate to an increased ability of the chimeras to bind
2F5 and, therefore, elicit 2F5-like antibodies upon
immunization of animals.
We performed this work with several ELDKWA chimeras
generated previously (namely B1-16, B2-16, C1-8, D1-4, and
F1-0 [42]) as well as with additional chimeras that were
generated anew from the same library (2F5 Library I, Figure 1).
We also designed, generated (when possible), and selected
chimeras from a number of additional libraries encoding the
2F5 epitope (2F5 Libraries II and III, Figure 1). In each case,
the epitope was inserted in such a way as to replace a small
segment of the VP2 puff, the site engineered most successfully
in our previous work [35,40,41].
Using advanced molecular dynamics methods to sample and
cluster epitope conformations for optimization of their
conformational propensity and exposure, we arrived at a
predicted structure for B1-16 [42], illustrated in Figure 2. This
chimera was generated from 2F5 Library I, for which DNA
oligonucleotides were synthesized that encoded the ELDKWAS
sequence flanked on either side by two randomized amino
acids (encoding any of the 20 commonly occurring amino
acids), enhancing the chances of identifying chimeras with
favorable growth characteristics and well presented ELDKWAS
inserts. The DNA oligonucleotides were hybridized, extended in
the region of the unique, randomized sequences, and ligated
into a plasmid, pST-LIC, that encodes HRV14 (except for the
region corresponding to the VP2 puff, to ensure that only
recombinant plasmids would be capable of producing infectious
RNAs). The recombinant plasmids were amplified in bacteria
and then purified for use as templates for in vitro transcription
reactions.
This purified ELDKWAS-encoding chimeric HRV plasmid
library was subjected to in vitro transcription to produce
infectious RNAs. After transfection of the RNA library into H1-
HeLa cells, a pool of chimeric viruses was produced,
containing approximately 6 X 103 independent viruses
(measured as a function of the number of plaques obtained by
transfection). The chimeric virus pool was propagated and
purified at this stage so that viruses selected for further study
might be more easily purified at later stages.
2F5 Library II.  A second library was designed to be like the
2F5 Library I with the addition of the leucine residues that flank
the ELDKWAS epitope among most HIV-1 isolates (2F5 Library
II, Figure 1). The inclusion of the leucines was based on the
observation that the Ac-LELDKWASL-NH2 peptide was seen to
bind 2F5 with nearly three orders of magnitude greater affinity
than the Ac-ELDKWAS-NH2 peptide [61]. Library II was
produced using the same methods as those used to produce
Library I. Oddly, only a single chimeric virus sequence was
found in this library among five sequenced at the plasmid level.
2F5 Library III.  A third library was designed with the
extended LELDKWASL sequence, this time removing one of
the randomized flanking residues on each side (2F5 Library III,
Figure 1). Library III was produced using the same methods as
those used to produce Libraries I and II. Production of this
library also led to an unexpected result: while the plasmids
generated were found to be normal, no viruses were obtained
from the plasmids using conditions that normally would have
yielded hundreds of viable viruses.
Immunoselection of Library I
In order to select for viruses that would ideally present their
ELDWAS sequences in ways resembling those of HIV-1,
viruses from Library I were immunoselected in one round on
the basis of their ability to bind to immobilized mAb 2F5 in the
presence of 0-32 pmol of competing peptide (Ac-
EQELLELDKWASLW-NH2; Figure 3). The chimeric viruses
thus selected grew at rates comparable to that of wild-type
HRV14, indicating that the presence of the inserts was not
deleterious to their growth. We observed a non-random
preponderance of P and G residues among the flanking
residues on both sides of the insert, with both P and G known
for promoting β-turns (and with Ps also known for disrupting β
sheets; Table 1). This might be related to structural features of
the engineered loop that affect the stability or acceptable
folding of the chimeric viruses that are compatible with the
ability to bind 2F5 [42]. As with their unselected counterparts,
the sequenced viruses were all seen to have intact ELDKWAS
epitopes.
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Antigenic characteristics of isolated chimeric viruses
A molecular dynamics study was directed toward maximizing
the conformational propensity for the β-turn conformation of the
epitope inserted onto the chimeric HRV. Affinity measurements
obtained from direct and competitive enzyme-linked
immunosorbent assays (ELISAs; using 2-16 pmol of Ac-
EQELLELDKWASLW-NH2 peptide/well), confirmed our
predictions that chimeras immunoselected in the presence of
the greatest concentration of peptide were able to best bind
immobilized mAb 2F5 ( [42] and unpublished data). Consistent
with this observation were chimera-antibody binding data from
quantitative fluorescence-quenching experiments [42]. Two
chimeras, B1-16 and C1-8, showed the greatest affinity to the
immobilized 2F5.
Figure 2.  The ELDKWA epitope of chimeric virus B1-16 (shown in purple) docked with the surface of the 2F5
paratope.  The protomeric unit of HRV, 60 of which come together to make the viral capsid, is in the bottom of the image and one of
the Fv domains of the 2F5 antibody is in the top. The viral proteins are colored blue for VP1, green for VP2, and red for VP3, and
the heavy and light chains of 2F5 are respectively in orange and light blue.
doi: 10.1371/journal.pone.0072205.g002
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Analysis of the chimeric virus sequences
Viral RNAs were reverse transcribed and sequenced to
confirm the presence of ELDKWAS sequences. Despite the
fact that only one chimeric virus was obtained from Library II
and no chimeras were produced from the plasmids generated
from Library III, all chimera sequences that were obtained from
Library I were found to be appropriate and without apparent
mutations (Table 1).
Immunization of guinea pigs and characterization of
immunogenicity of chimeric viruses
Given their favorable antigenic profiles [42], chimeras B1-16
and C1-8 from Library I were chosen for immunization studies
to see if they could elicit 2F5-like antibodies in guinea pigs. We
immunized three guinea pigs with each chimera using a prime-
boost strategy. Immunizations consisted of subcutaneous
injections of 40 µg of mini-purified virus at weeks 0 and 4
followed by immunizations at weeks 9 and 13 with 40 µg of
mini-purified chimeric virus and 80 µg of a keyhole limpet
hemocyanin (KLH)-conjugated C-EQELLELDKWASLW-NH2
peptide. Sera were collected at week 16, after which their
neutralizing abilities were tested against 12 HIV-1
pseudoviruses that contained envelope sequences from
diverse subtypes (A, B, C, D, AE, and F) and with varying co-
receptor usages (X4 and R5). It should be noted that the
chimeric HRVs do not replicate in guinea pigs, making them
only a rough screen for the types of immune responses that
might be possible upon immunizing with live viruses in people.
Table 2 shows the overall neutralization activity of six serum
samples elicited from two ELDKWA-displaying chimeric
viruses. Positive controls consisted of serum from an HIV-1-
positive patient, Z23, as well as purified mAb IgGs 2F5 and
4E10; negative controls consisted of pooled serum from six
guinea pigs immunized with a non-engineered HRV14 and the
non-HIV-1 pseudovirus, amphotropic murine leukemia virus
(αMLV). The neutralization titers are expressed as reciprocal
titers at which 40% inhibition of neutralization was observed
(compared with pooled normal guinea pig serum values). While
some neutralization elicited 50% inhibition, a 40% cut-off
allowed us to identify more chimeric viruses that could be
worthy of optimization for future immunogen development.
The C1-8 chimeric virus failed to generate detectable
neutralization activity against any of the isolates examined. In
contrast, the B1-16 chimera elicited neutralizing activity for all
three guinea pigs tested. The greatest response was seen in
the sera’s ability to neutralize the 92TH024 pseudovirus (of
subtype AE; co-receptor type R5), with IC40 reciprocal
neutralizing titers of 70, 80, and 80. The 93BR029 pseudovirus
Table 1. Sequences of the most antigenic chimeras
immunoselected and characterized from 2F5 Libraries I and
II.
Chimeric viruses HRV N linker Core epitope C linker HRV
ELDKWAS Library I Chimeras
B1-16 … DLSS HG ELDKWAS PN GGP…
B2-16 … DLSS GK ELDKWAS QP GGP…
C1-8 … DLSS PG ELDKWAS IP GGP…
D1-4 … DLSS SP ELDKWAS LP GGP…
F1-0 … DLSS PP ELDKWAS SP GGP…
Lib 1-1 … DLSS PG ELDKWAS SR GGP…
Lib 1-2 … DLSS GV ELDKWAS AP GGP…
Lib 1-3 … DLSS PG ELDKWAS PN GGP…
ELDKWAS Library II Chimera
Lib 2-1 … DLSS SS LELDKWASL HP GGP…
2F5 Library III did not produce live viruses.
doi: 10.1371/journal.pone.0072205.t001
Figure 3.  Docking of HRV14 (shown in yellow) with a crystallographic structure (1TZG from the Protein Data Bank) of a
complex of the 4E10 Fab (orange) complexed with the cognate Ac-KGWNWFDITNWGK-NH2 peptide (blue ribbon and gold
stick-and-balls model).  Docking provides ideas for how to connect the 4E10 epitope to the surface of HRV.
doi: 10.1371/journal.pone.0072205.g003
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Table 2. Neutralization of HIV-1 pseudoviruses from antisera collected from guinea pigs immunized with chimeric viruses
(and boosted with MPER-encoding peptides).


























2F5: ELDKWA              
B1-16:
GFA-292
<20 <20 <20 <20 <20 <20 <20 <20 <20 <20 70 30 <20
B1-16:
GFA-293
<20 <20 <20 <20 <20 <20 <20 <20 <20 80 80 30 <20
B1-16:
GFA-294
<20 <20 <20 <20 <20 <20 <20 <20 <20 20 80 50 <20
C1-8: GFA-289 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
C1-8: GFA-290 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
C1-8: GFA-291 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
4E10:
NWFDIT(K/N)
             
01A3: GFA-286 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 20 <20 <20
01A3: GFA-287 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
01A3: GFA-288 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
02A1: GFA-280 <20 <20 <20 <20 <20 <20 <20 <20 <20 25 45 35 <20
02A1: GFA-281 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 20 <20
02A1: GFA-282 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 35 35 <20
02B2: GFA-283 <20 <20 <20 <20 20 <20 <20 <20 <20 <20 35 <20 <20
02B2: GFA-284 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
02B2: GFA-285 <20 <20 <20 <20 25 <20 <20 <20 <20 35 60 40 <20
11A2: GFA-271 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
11A2: GFA-272 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
11A2: GFA-273 <20 <20 <20 <20 25 <20 <20 <20 <20 <20 <20 40 <20
13A3: GFA-274 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
13A3: GFA-275 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
13A3: GFA-276 <20 <20 <20 875 <20 <20 <20 <20 <20 <20 <20 <20 <20
12B1: GFA-277 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 30 <20 <20
12B1: GFA-278 45 60 <20 <20 30 50 35 40 40 45 80 50 20
12B1: GFA-279 <20 30 <20 <20 <20 70 <20 20 <20 20 90 70 25
13C2: GFA-268 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
13C2: GFA-269 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
13C2: GFA-270 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
21B1: GFA-262 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 20 <20
21B1: GFA-263 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
21B1: GFA-264 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 20 <20
21D1: GFA-265 <20 30 <20 30 <20 35 <20 20 <20 35 70 40 40
21D1: GFA-266 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
21D1: GFA-267 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
22C1: GFA-259 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 25 <20
22C1: GFA-260 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 25 70 <20
22C1: GFA-261 <20 <20 <20 20 20 45 <20 20 <20 45 50 85 <20
Controls              
HRV14 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
2F5 (µg/ml) 3.6 0.2 0.006 0.016 0.04 0.28 >100 >100 1.0 1.2 0.04 0.17 >100
4E10 (µg/ml) 5.5 0.66 0.02 0.19 0.12 1.3 2.5 0.11 0.15 1.2 0.11 0.18 >100
Z23 1,000 1,100 31,500 14,000 6,500 1,700 2,500 1,000 7,100 2,200 1,000 5,600 90
The numbers correspond to the reciprocal of the dilution of the guinea pig sera at which the luciferase expression is reduced by 40% (IC40). One negative control is the
related but non-HIV-1 pseudovirus, amphotropic murine leukemia virus (α-MLV). Another negative control is HRV14 without any of the HIV MPER inserts. The positive
control is serum from an HIV-infected person; guinea pig titers are expected to be lower as HIV does not replicate in guinea pigs.
doi: 10.1371/journal.pone.0072205.t002
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(of subtype F; co-receptor type R5) was neutralized with IC40
titers of 30, 30, and 50. The 92UG005 pseudovirus (of subtype
D; co-receptor type R5) was neutralized by one of the guinea
pig sera with an IC40 titer of 80.
Construction and Production of the Three
Combinatorial 4E10 Libraries
4E10 Library I.  A complex library was constructed to
encode both the 2F5 and 4E10 epitopes in tandem in place of
part of the VP2 puff of the NIm-II region of HRV14 (4E10 Lib I,
Figure 1). The 2F5 and 4E10 epitopes are naturally adjacent in
the context of HIV-1, offering the hope that their joint inclusion
might enhance our ability to present them in native-like
conformations and to maximize the opportunities for eliciting an
effective immune response. The 4E10 epitope consists largely
of the tryptophan-rich, contiguous sequence N671WF(D/N)
ITNWLW680 [33,62,63,64,65] and is recognized by the 4E10
mAb, one of the most broadly neutralizing anti-HIV antibodies,
capable of neutralizing virus isolates from all group M HIV-1
subtypes [21,63,66,67]. Crystallographic and NMR studies
have demonstrated that the 4E10 epitope adopts an
amphipathic helical conformation, significantly embedded in the
viral membrane and varying in the extent to which it is slightly
bent or straight in the middle of the epitope, depending on the
constructs and conditions used [29,33,57,65,68]. The binding
of mAb 4E10 to the epitope appears to create a more
significant angle at the bend between the two α-helical
segments of the MPER epitope region [29], initiated when the
CDR H3 loop extracts W672 and F673 from the viral
membrane, promoting neutralization. The 4E10 epitope
overlaps with that of the Z13e1 epitope, W670NWFDITN677 [69].
The Z13e1 epitope consists of a two-helix structure with a
hinge near D674, which distinctly kinks and rigidifies upon
binding by Z13e1 [28,57,29].
For the 2F5 epitope, the (E60/A40) LDKWA sequence was
chosen, reflecting the approximate serodiversity of E (60%)
and A (40%) residues in the Los Alamos Database at the time
of the design. For the 4E10 epitope, a more complex sequence
was chosen than those used for the 2F5 chimeras, reflecting
the more diverse sequences found in the Los Alamos
Database as well as our attempt to mitigate some of the
extremely hydrophobic nature of the epitope (to avoid problems
with its presentation on the solvent-exposed surface of
HRV14). We chose the following sequences (with the
subscripts representing the percentages of the residues found
at any given site for any cases where its value was less than
100%):
We represented the 1-3 key residues found at any given site
for this epitope and, in all cases except those that appeared to
be both invariant and critical to interaction with 4E10, we
allowed for 50% randomization of the residue (X, encoding any
of the 20 amino acids, with the remaining percent reflecting the
natural ratios of the given residues seen among HIV-1
isolates). The same reasoning was used to encode the three
residues between the epitopes. A mixture of HIV residue
sequences and randomized sequences was also used for the
linkers that flanked the tandem epitope, with one added degree
of complexity: variability of the length of the linkers. These
linkers varied from 1–4 residues in length, which provided
additional chances for getting the orientation of key residues
appropriately presented. Unfortunately, we were unable to
obtain any chimeric viruses that displayed both epitopes.
4E10 Library II.  A second 4E10 combinatorial library was
constructed that was similar in design to Library I but without
the 2F5 epitope (4E10 Lib II, Figure 1). The 4E10 epitope
chosen corresponded to the same residues except we replaced
the C-terminal W with an A, removed the randomization of the
epitope residues, and adjusted a few percentages of the HIV
residues to confer a slightly more hydrophilic balance. In
addition, instead of encoding 1-4 linker residues, the epitope
was flanked by 1, 2, 4, or 6 residues (roughly half of which
were randomized and half of which represented the key HIV-1
residues found at each site).
Anticipating possible viability problems, this library was
constructed in 16 subpools, by separately combining each of
the four N-terminal DNA oligomers with each of the four C-
terminal DNA oligomers. For most of the subpools, no viable
chimeric viruses were obtained, particularly for the subpools
designed with longer oligomers. For the chimeric viruses that
were obtained, the corresponding plasmid sequences were all
found to be intact; however, the transcribed viral RNAs were
typically characterized by multiple point mutations and
deletions (data not shown). In fact, the only chimeric viruses
found to have intact or nearly intact viral RNA sequences were
those that had an N-linker length of one and a C-linker length
of either one or four (both of which could present an α-helical
structure in the same register).
4E10 Library III.  A third 4E10 combinatorial library was
constructed by trimming the epitope down to its most essential
components (including the N671 and D674 residues critical for
neutralization by Z13e1 [69] to allow for the presentation of
either or both epitopes; Figure 1). With known X-ray
crystallographic structures of the 4E10 Fab bound to a number
of cognate epitope peptides, we juxtaposed the
LWNWFDITNW 4E10-peptide complex structure (PDB ID
2FX7) with that of the VP2 puff region of HRV14 (Figure 4) to
design a third library aimed at conserving the integrity of the
structure of both the HIV epitope and HRV. With the goal of
inserting an HIV epitope with linkers of optimal length to “fit” in
place of the HRV loop and promote the helical conformation of
the 4E10 peptide seen crystallographically, we chose the
immunogenic sequence, NWFDIT, flanked on the C-terminal
side of the epitope by the prevalent N or K residues (25%
prevalence each, as well as 50% randomized residues), with
an additional 1-3 linker residues on each side of the epitope.
On the N-terminal side of the epitope, half of the linker residues
were randomized and half were coded to be the α-helix-
promoting A and E residues and the more hydrophilic bend-
and turn-promoting D (Figure 1).
After sequencing the viral RNA, the intact 4E10 epitope
(NWFDIT) was observed in 16 of 33 chimeric viruses (found in
Cold Viruses Displaying HIV-1 gp41 Immunogens
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e72205
X50   W   F   X50 I T75 X50 X50
N37.5 D37.5 S25 N30 W50
S12.5 N12.5 K20
11 of the 16 sub-libraries examined; unpublished data). Among
the 17 mutated viruses, all but one involved mutation of the
strongly hydrophobic tryptophan residue, indicating that the
hydrophobicity of this residue was detrimental to the viability of
the chimeras. As with 4E10 Library II, most of the frame-shift
mutations were observed among chimeras with the greatest
number of linker residues, suggesting that longer linkers led to
reduced viral fitness. When analyzing the linker residues of the
viruses with intact 4E10 epitopes, the linker residues were
found to be more abundant on the C-terminal side of the
epitope, with an average of 1.7 vs. 1 residues/linker (for the C
vs. N linker). For the biased residues encoded to be D, A, and
E, E was favored [representing 20/38 (57%) of the D/A/E
biased residues vs. an expected percentage of 33%]. Among
the randomized residues, there was a preponderance of G
residues in the N-linkers, particularly for the chimeras with
longer linkers, suggesting that the G residues may have been
serving a role in disrupting the secondary structures that would
have otherwise characterized these linkers.
Immunoselection of Library III
To enrich for the most immunogenic chimeric isolates, the 11
(of 16) individual combinatorial sub-libraries seen to have
chimeras with mostly or completely intact 4E10 epitopes were
subjected to immunoselection (Figure 5). Initial experiments
were performed with both the 4E10 and Z13e1 IgGs, but we
were unable to obtain specific and selective binding with either
of two sublibraries tested using Z13e1 (L12 and L13);
therefore, subsequent immunoselections were all performed
with 4E10 alone. After one of the individual sub-libraries, L20,
showed poor antigenicity (i.e., poor ability to bind 4E10) after
the first round of immunoselection, it was eliminated from
further immunoselection studies, leaving 10 sub-libraries that
were subjected to two rounds of immunoselection.
Two different immunoselection schemes were employed for
the 10 libraries (Figure 5). For libraries L00, L01, L02, L03,
L10, L11, L12, and L13, two rounds of competitive
immunoselections were used. In the first round of competitive
immunoselection, 13.3 nM of 4E10 antibody was coated on the
Figure 4.  Immunoselection scheme used with 2F5 Library.  I. The 2F5 Library I was subjected to selection using varying
amounts of competitive peptide Ac-EQELLELDKWASSLW-NH2 in hopes of finding chimeras that were well recognized by 2F5. The
chimeras used for immunization studies were subjected to a single round of immunoselection.
doi: 10.1371/journal.pone.0072205.g004
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immunoplates, and then 0-320 nM of the 4E10-epitope peptide
[designated NK-15 (with the helix-promoting K7-D11 lactam-
bridged sequence Ac-NWFDITK 7WLWD 11KKK-NH2)] was
used to compete with the input library viruses for binding to the
4E10 antibody. After washing away unbound material, H1-
HeLa cells were seeded in the wells and the resulting subpools
of viruses harvested were collected and characterized by direct
ELISA. In each case, the subpool that bound 4E10 with the
highest average affinity was used for the second round of
immunoselection. The second round of immunoselection was
more stringent, employing 6.7 nM of 4E10 antibody and 0-640
nM peptide. In contrast, libraries L21 and L22 were not
subjected to competitive binding of virus to antibody. After
these chimeras were allowed to bind to 13.3 nM 4E10,
750-3000 nM NK-15 peptide was used to elute the bound
viruses (prior to cellular elution). Differentially eluted subpools
were collected and characterized. The subpools with the
greatest average affinity to 4E10 were followed by further
immunoselection using either 6.7 nM 4E10 and 0-640 nM
competitive peptide or 0.84 nM 4E10, no competitive peptide,
and 75-6000 nM peptide for elution.
To evaluate the effects of immunoselection on the enriching
of chimeric viruses with enhanced 4E10 binding affinity, direct
ELISAs were performed. Figure 6 shows an example of two
rounds of immunoenrichment with library L13. The ELISA
reflects that the binding affinity varies significantly for viruses
from different subpools, with the highest concentrations of
competitive peptide used during immunoselection being
associated with greater average binding affinity of the viruses
to immobilized 4E10 (Figure 6A). In contrast, a 2F5 chimeric
virus, 14-C40-1 (which expresses the 2F5 epitope in lieu of the
4E10 epitope), was not influenced by the 4E10 peptide
concentration. It appears that there was no further
immunoselection achieved in the second round (Figure 6B),
reflected by the lack of significant differences of the OD450
values for the 10-640 nM peptide-selected subpools.
Antigenic characteristics of immunoselected chimeric
viruses from Library III
After two rounds of immunoselection, viral plaques were
isolated from each immunoselected virus pool. The virus
isolates were subjected to two rounds of plaque purification
and then propagated. Propagated virus lysates were assayed
using direct ELISAs to characterize their antigenicity. In a
preliminary ELISA, 30 virus samples were compared. The 10
viral isolates that were found to bind 4E10 most tightly were
further propagated, partially purified, and subjected to
additional characterization by direct ELISA, competitive ELISA,
and MTT neutralization assays.
Direct ELISAs, performed with 9 of the 10 chimeras chosen
for further study, showed significant antibody binding for 6 of
the viruses tested (cf. 22C1, 11A2, 21B1, 12B1, 21D1, and
13C2; Figure 7A). The others (13A3, 02B2, and 02A1) bound
4E10 with affinity barely greater than that of the 14-C40-1
chimera containing the 2F5 epitope in lieu of the 4E10 epitope,
indicating that they most likely had bound 4E10 in the
Figure 5.  Immunoselection scheme used with 4E10 Library III.  The sub-libraries were subjected to varying selection schemes
in hopes of finding chimeras that were well recognized by 4E10. All of the chimeras used for immunization studies were subjected to
two rounds of immunoselection, some in the presence of competitive peptide NK-15.
doi: 10.1371/journal.pone.0072205.g005
Cold Viruses Displaying HIV-1 gp41 Immunogens
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e72205
Figure 6.  Direct ELISAs reflecting the impact of immunoselection of 4E10 library III, sub-library 13.  Immunoselection was
performed by immobilizing 4E10 and capturing chimeras that could bind in the presence of varying amounts of competing 4E10
peptide.
A. 1st round: Immobilized 4E10 mAb treated with library 13 plus competitive peptide.
B. 2nd round: Immobilized 4E10 mAb treated with Pool A from 1st round plus competitive peptide.
doi: 10.1371/journal.pone.0072205.g006
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immunoselections predominantly via non-specific hydrophobic
interactions. It appears to be significant that two of the three
poor 4E10 binders lack N-terminal linkers altogether and that
the third chimera has helix-disrupting P residues on both sides
of the core epitope.
Using a competitive ELISA format, we tested the ability the
10 chimeric viruses that bound 4E10 best in the
immunoselections to compete with the constrained 4E10
epitope peptide, NK-15, for binding to the 4E10 antibody. The
observations paralleled those of the direct ELISA (Figure 7B).
Five of six of the viruses with the greatest affinity to 4E10 in the
presence of competitive 4E10 peptide were the same as those
found using the direct ELISAs without the peptide (e.g., 21D1,
22C1, 21B1, 13C2, and 12B1, but not 11A2). It may be
noteworthy that the sixth chimera, 11A2, which bound poorly in
the competitive ELISA chimera, is the only chimera that bound
in the apparently less stringent direct ELISA that has only a
secondary-structure-disrupting S residue in its N-terminal linker
(and may not be able to accommodate possible structural
requirements for optimal 4E10 binding).
MTT neutralization assays were also employed to
characterize the antigenicity of the 10 chimeric virus isolates
(Figure 7C). In this case, we asked if 4E10 could recognize the
transplanted HIV epitope, now on the heterologous virus,
HRV14, and in so doing, neutralize the ability of the chimeric
HRV to infect its host cells, H1-HeLa cells. While this test did
not point to the same 5 or 6 viruses as the ELISAs, two of the
six viruses, 21D1 and 13C2, stood out as being clearly
recognized and neutralized by 4E10 in a dose-dependent
manner. In addition, 4E10 did display some mild neutralization
of three of the other four chimeras that had scored well in the
ELISAs, 11A2, 21B1 and 22C1, further verifying that some
aspects of the antigenicity of the 4E10 epitope in the context of
these five chimeric viruses was recognized by 4E10 in the
context of HRV.
Sequence analysis of the immunoselected chimeric
viruses from Library III
The sequences of the foreign epitopes of the 10 4E10
epitope-containing chimeric viruses that best bound 4E10 in
the three antigenicity assays were determined (Table 3). Unlike
the chimeric viruses of Libraries I and II, all 10 of the chimeras
sequenced from Library III contained full-length, unmutated
4E10 core epitope sequences. However, a non-random
distribution of residues was found in both linker regions.
The N-terminal linker was expected to consist of 1-3
residues, 50% of which were randomized and 50% of which
were equally distributed among D, A, and E. Surprisingly, the
linkers were found to have 0-2 residues instead (despite having
1-3 residues in the sequenced plasmids). Furthermore, the N-
terminal linkers were populated with more E and D residues
than expected (accounting for 7 of the 10 residues vs. 4 of 10
expected), generating an observed average charge per linker
of -0.7 (vs. -0.33 expected; this is in contrast to their pre-
immunoselected counterparts, which had normal charge
distributions of the N-linker residues). The E residues (3 of the
10 residues) strongly promote α-helices and D residues (4 of
the 10 residues) are known to promote β turns. The remaining
Figure 7.  Antigenicity assays reflecting differences among
individual chimeric viruses.  A. Direct ELISA using 4E10 to
capture the chimeras.
B. Competitive ELISA using 4E10 to capture chimeras that
could bind in the presence of competitive peptide, NK-15.
C. MTT cell-killing assay using 4E10 to bind to and neutralize
the chimeric viruses, preventing HeLa cell death.
doi: 10.1371/journal.pone.0072205.g007
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three N-terminal linker residues consisted of two S residues
and one P residue, both of which are known to disrupt
secondary structures and promote β turns. The propensities of
the N-terminal linker residues to promote α-helices were similar
for the selected and unselected chimeras from 16 subpools
pre-immunoselection (18 of which were mutated in the
NWFDIT epitope region; Table S1). The immunoselected
chimeras exhibited 30% α-helix-promoting residues vs. 38.7%
observed for the unselected chimeras. It is interesting to note
that both the selected and unselected chimeras had fewer α-
helix-promoting N-linker residues than was expected from the
nucleotide sequences used (53.1%), most likely reflecting a
cost to fitness of the chimeric viruses. In contrast, the
propensity of the N-terminal linker residues to promote β turns
was significantly increased by immunoselection [promoted by
7/10 residues (70.0%) vs. 26% expected]. In addition, like the
N-terminal linker residues of the selected viruses, those of the
unselected viruses were shorter on average than expected
(with only 2 of 33 chimeras having N linkers with 3 residues in
length).
The C-terminal linkers of the 10 immunoselected chimeras
that best bound 4E10 were found to be of the expected lengths
(with a modest preference for shorter linkers); however, their
sequences were non-random in nature. At the position C-
terminal to the core epitope sequence, designed to encode
50% randomized residues and 25% each of the HIV-1 residues
at that site, N (an α-helix and β-sheet breaker) and K (an α-
helix promoter), only N and K were found. Unfortunately, this
observation was also found for 20 of the 25 intact unselected
chimeras and even for 9 of 11 plasmid DNAs.
C-terminal to the X/N/K residue, the chimeras were designed
to have their linker residues 50% randomized and 50% (D/A/E).
The observed average charge of the C-terminal linker residues
was -0.47 (vs. -0.33 expected). In addition, the amino acid
Table 3. Sequences of the most antigenic chimeras
immunoselected and characterized from 4E10 Library III.
Chimeric viruses HRV N linker Core epitope C linker HRV
4E10 Library III Chimeras
01A3 … DLSS  NWFDIT N E VGG…
02A1 … DLSS  NWFDIT K EE VGG…
02B2 … DLSS  NWFDIT K LE VGG…
11A2 … DLSS S NWFDIT N E VGG…
12B1 … DLSS P NWFDIT K EP VGG…
13A3 … DLSS E NWFDIT N EAN VGG…
13C2 … DLSS E NWFDIT N NLV VGG…
21B1 … DLSS DD NWFDIT N T VGG…
21D1 … DLSS SD NWFDIT N E VGG…
22C1 … DLSS DE NWFDIT K N VGG…
Most chimeras isolated from the 4E10 libraries I and II were found to have
deletions or mutations in their inserted sequences. Most chimeras from Library III
had correct sequences (matching the design). This set represents those
determined to have the most promising antigenic characteristics and, therefore,
chosen for immunization studies in guinea pigs.
doi: 10.1371/journal.pone.0072205.t003
distribution was non-random (Table S1), reflecting fitness
needs for epitope presentation on HRV (in the case of
unselected chimeras) and attributes that favored binding to
4E10 (in the case of the immunoselected chimeras). Oddly,
there were no bend- and turn-promoting D residues observed
among the immunoselected viruses (vs. 3-4 expected).
Instead, 12 of the 17 linker residues (70.6%; Table S1) were α-
helix-promoters (8 E, 2 L, 1 A, and 1 V) and 12 (70.6%) were β-
sheet breakers (8 E, 1 P, and 1 T). Whether immunoselected
or not, the C-terminal linker residues displayed slightly more
negative charge than expected (-0.44 per linker vs. -0.33
expected). Regarding the amino acid distribution,
immunoselection led to increases in the presence of C-terminal
linker residues that promoted α-helix formation, β-sheet
disruption, and β-turn formation. α-helix formation was
promoted by 70.6% of the selected linker residues vs. 60.5%
for the unselected set and 53.1% expected at the nucleotide
level. β-sheet disruption was also promoted by 70.6% of the
selected linker residues vs. 52.6% for the unselected set and
25.0% expected at the nucleotide level. β-turn formation was
promoted by 40% of the selected linker residues vs. 31.6% for
the unselected set and 26.6% expected at the nucleotide level.
Physical appearance of isolated chimeric viruses from
Library III
Transmission electron microscopy was performed with each
of the chimeric viruses chosen for immunization studies (one of
which is exemplified in Figure 8). All preparations of mini-
purified viruses were seen to include a noticeable fraction of
viruses that were not fully assembled, as evidenced by the
presence of pentameric subunits (12 of which come together
normally to form the intact virus coat) uncharacteristic of wild-
type HRV14. In addition to electron microscopy, dynamic light
scattering revealed that the chimeric viruses studied were
monodisperse in the concentration ranges used (unpublished
data).
Immunization of guinea pigs and characterization of
immunogenicity of Library III chimeric viruses
To characterize the ability of the chosen 10 chimeric viruses
to elicit 4E10-like antibodies, we immunized guinea pigs (three
per chimera) using a prime-boost strategy. Immunizations
consisted of subcutaneous injections of 40 µg of mini-purified
virus at weeks 0 and 4 followed by immunizations at weeks 9
and 13 with 40 µg of mini-purified chimeric virus boosted with
80 µg of the KLH-conjugated lactam-bridged 4E10 epitope
peptide, NK-15, shown to bind 4E10 with the greatest affinity
from a series of peptides tested [70]. Sera were collected three
weeks later after which their neutralizing abilities were tested
against 12 HIV-1 pseudoviruses that contained envelope
sequences from diverse subtypes (A, B, C, D, AE, and F) and
co-receptor usages (X4 and R5).
The data were generated as neutralization curves,
exemplified by the Figure 9 curves obtained with guinea pig
serum GFA-278 (from immunization with chimeric virus 12B1).
The neutralization titers were expressed as reciprocal titers at
which 40% inhibition of neutralization was observed compared
with pooled normal guinea pig serum values. Only a few serum
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samples were able to generate 50% inhibition of infection by
the HIV‑1 pseudoviruses, so the less stringent cut-off of 40%
inhibition was chosen to help identify and differentiate chimeras
that could be further developed for possible use as vaccine
components. Given that human rhinovirus does not replicate in
guinea pigs, but does replicate in humans, it is possible that the
immune responses to the chimeras would be greater in
humans.
Table 2 shows the overall neutralization activity of the 30
serum samples elicited from the chimeric viruses as well as
pooled serum from six guinea pigs immunized with a non-
engineered HRV14, serum from HIV-1-positive patient Z23,
and purified mAb 2F5 and 4E10 IgGs. The non-HIV-1
pseudovirus, αMLV, was used as a negative control. We have
previously immunized guinea pigs with KLH-conjugated MPER
peptides alone, resulting in no significant neutralizing
responses [35]. Likewise, the lack of significant neutralization
elicited by the majority of the animals immunized in this study
(Table 2) further reflects that the peptides used were not able
to elicit neutralizing responses on their own. Whether or not the
Figure 8.  Transmission electron micrograph of a representative partially purified preparation of chimeric virus 11A2.  Intact
viruses are roughly 30 nm in diameter. Pentameric units, 12 of which come together to form the virus coat, can be seen as small
discs roughly 5 nm in diameter (with dark stain-filled centers), as can some smaller fragments, indicating that some viruses are not
fully assembled.
doi: 10.1371/journal.pone.0072205.g008
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Figure 9.  Representative neutralization curves reflecting the ability of antiserum GFA-278, derived from immunization with
chimeric virus 12B1, to neutralize 12 HIV pseudoviruses from six subtypes.  Neutralizing titers corresponding to 50% inhibition
of the reporter luciferase activity (compared with inhibition by pooled normal guinea pig serum values) is denoted by the dashed
lines.
doi: 10.1371/journal.pone.0072205.g009
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peptides provided a beneficial boosting of the immunity elicited
by the immunogenic chimeric viruses studied is not known, as
peptides were added for every immunization in this study.
As expected, significant differences can be seen comparing
the abilities of the chimeras to elicit neutralizing responses not
only among the different pseudoviruses, but also among the
different guinea pigs. The broadest neutralization of the
pseudoviruses was elicited by the serum sample GFA-278,
from chimera 12B1, which neutralized 10 of the 12 HIV
pseudoisolates, including the two subtype C pseudoviruses
(which are moderately neutralized by purified mAb 4E10 but
are not neutralized by mAb 2F5 [63]). At least one pseudovirus
of each subtype and co-receptor usage tested was neutralized
by serum from this chimera, with reciprocal titers ranging from
30 to 80. The other sera elicited by the 12B1 chimera,
GFA-277 and GFA-279 were not as inhibitory. GFA-277 only
neutralized one isolate, 92TH024 (subtype AE, with a rather
low titer of 30). GFA-279 neutralized four pseudoviruses of four
subtypes (92UG037 of subtype A, JRCSF of subtype B,
92TH024 of subtype AE, and 93BR029 of subtype F, with titers
ranging from 30–90). The αMLV pseudovirus was also
neutralized marginally by this serum sample (GFA-279),
suggesting that there may have been some degree of non-
specific neutralization activity by this serum. Notably, the 12B1
chimera was not among those best recognized by 4E10 in the
ELISAs (Figures 6 and 7), making it difficult to understand why
this serum displayed the broadest—and some of the strongest
—neutralizing ability. The GFA-265 serum sample elicited by
chimera 22D1 was also able to modestly neutralize six
pseudoviruses; however, this serum also had a comparable
neutralizing titer of 40 against αMLV, and the other two sera
from immunization with this chimera were inactive, suggesting
that the neutralizing activity of this serum is not likely to be
significant. In contrast, the neutralization spectrum seen in
response to 22C1 demonstrated specific and reproducible
neutralization of several pseudoviruses. All three guinea pig
sera neutralized 93BR029 (subtype F, with IC40 values of 85,
70, and 25) and two serum samples neutralized 92TH024
(subtype AE, with IC40 values of 50 and 25). In addition,
GFA-261 was also able to neutralize 92UG005 (subtype D) and
JRCSF (subtype B), both with a titer of 45. A spurious titer was
exhibited (repeatedly) for the GFA-276 serum elicited by
chimeric virus 13A3, registering 875 against the subtype B
NL43 pseudovirus; no other neutralizing activity was seen
against any of the other pseudoviruses for any of the three
serum samples against this chimera. Modest neutralization
responses were seen against the 02A1 and 02B2 chimeras.
Both elicited neutralization activity in two of three guinea pigs,
generally against the same pseudoviruses, most strongly
against 92TH024 (subtype AE, ranging from 35–60 in four of
six guinea pigs), 93BR029 (subtype F, with titers of 35 for two
of six guinea pigs) and 92UG005 (subtype D, with titers of 35
and 25 for two of six guinea pigs). Overall, the pseudoviruses
most frequently neutralized by the various serum samples were
92TH024 (subtype AE, also observed with a number of 2F5
chimeras [35]) and 93BR029 (subtype F), though the reason
for this is not clear.
Discussion
During natural infection, non-neutralizing antibodies appear
to be dominant in the antibody response directed against HIV-1
gp41 [71,72,73,74]. Using the chimeric HRV system to display
the MPER epitopes that elicited the broadly neutralizing mAbs,
2F5, 4E10, and Z13e1, we have attempted to focus the
immune response specifically to these conserved epitopes.
Many attempts have been made with little success using the
ELDKWA (2F5) epitope as a vaccine target (reviewed in Table
S1 of [35]). Similarly, many efforts to display the 4E10 epitope
have also failed to induce neutralizing antibodies [64,75].
Unfortunately, significant MPER-directed neutralization has
been limited [15,35,36,37,38,39]. It is likely that the vaccine
candidates tested thus far do not sufficiently resemble the HIV
epitopes in their most immunogenic conformations.
In our previous studies [35,42], we engineered the 2F5
epitope based on structural considerations and constructed a
series of combinatorial ELDKWA libraries comprising millions
of chimeric viruses with different structures. Following
immunoselection with 2F5, we were able to elicit neutralizing
antibodies in animal models. For this study, armed with
additional structural information, we designed new
presentations of the 2F5 epitope. We aimed to present the 2F5
epitope to be well exposed, and with the addition of the flanking
N- and C-terminal hydrophobic L residues that were shown to
increase peptide binding to 2F5 by three orders of magnitude
[61]. Our previous efforts to present the flanking L residues
were unsuccessful in the context of HRV [35] and, in this study,
the presence of the flanking L residues was associated with
neutralizing titers that were less broad and, in some cases, less
potent than those obtained from our prior efforts. Nonetheless,
one of the two ELDKWA-presenting chimeras was able to elicit
neutralizing antisera in all three guinea pigs tested. Two of the
antisera were able to neutralize pseudoviruses of two subtypes
and the third antiserum was able to neutralize pseudoviruses of
three subtypes.
We also used a structure-based strategy for presenting the
4E10 epitope. In this case, the designs included the essential
HIV residues and also the goal of maintaining the α-helix
conformation recognized by 4E10, all using the combinatorial
approach characteristic of our previous efforts (to increase the
chances of generating the desired structures) combined with
the high-throughput screening. This semi-rational, brute-force
effort resulted in the production of three 4E10-epitope-
displaying libraries. The first two such libraries were met with
viability challenges and/or deletions in the region of the foreign
epitope. The third library was more successful and most
individual chimeras examined retained the intact epitope and
demonstrated high specificity of binding to 4E10, particularly
following immunoselection. In contrast, attempts to
immunoselect chimeras with the Z13e1 antibody did not lead to
specific binding, demonstrating a distinction between the
epitopes of Z13e1 and 4E10.
Sequence analysis revealed significant effects of virus
viability and antibody-binding capabilities upon the distribution
of linker residues found flanking the 4E10 epitope (Table 3 and
Table S1). In the N-terminal linker, the percentage of α-helix-
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promoting residues found was lower than expected among
unselected chimeras (38.7% vs. 53.1% encoded) and reduced
further following immunoselection with 4E10 (to 30.0%). In
contrast, the percentage of β-turn promoting residues was
strikingly increased as a function of being presented on the
surface of HRV (48.4% vs. 26.6% encoded), and this was even
more dramatic following immunoselection (70.0%). Despite the
reduction in α-helix-promoting residues in the N-terminal linker,
the net result was that the percentage of chimeras with either
α-helix- or β-turn promoting residues in their N linkers was
100% for the immunoselected chimeras, in contrast to being
80.6% for the unselected chimeras.
At the C-terminal linker, beyond the N- and K-biased linker
residue, immunoselection led to a significantly greater fraction
of α-helix-promoting residues, β-sheet-disrupting residues, and
β-turn-promoting residues (Table S1). The percentages of α-
helix-promoting residues increased from 60.5% among
unselected chimeras to 70.6% for immunoslected chimeras (vs.
53.1% encoded). Likewise, the percentages of β-sheet-
disrupting residues increased from 52.6% among unselected
chimeras to 70.6% for immunoselected chimeras (vs. 25.0%
encoded). Similarly, the percentages of β-turn promoting
residues increased from 31.6% among unselected chimeras to
40.0% for immunoselected chimeras (with 26.6% encoded).
The N and C linker distributions of the 4E10 chimeras clearly
reflect crucial roles of the residues present. Regarding viral
fitness, benefits were seen on (a) the N-terminal side from
reductions in the percentages of α-helix-promoting residues
and increases in the percentages of β turn-promoting residues
and (b) the C-terminal side from the presence of α-helix-
promoting residues, β-sheet-disrupting residues, and β-turn
promoting residues. Regarding binding of the engineered
epitope to 4E10, benefits were seen on (a) the N-terminal side
from the presence of even greater reductions in the
percentages of α-helix-promoting residues and greater
increases in the percentages of β-turn-promoting residues and
(b) the C-terminal side from increases in the α-helix-promoting
residues, β-sheet-disrupting residues, and β-turn promoting
residues. While we can only conjecture about these amino acid
distributions, it is interesting to note that: (1) β-turns are
typically the dominant secondary structure of antibody-bound
peptides [76] and (2) it may be that β turns in these chimeras
enabled the 4E10 epitope to maintain the α-helicity that
appears to be necessary for 4E10 binding [64,65]. In this
regard, it may be significant that the most broadly immunogenic
chimeric virus identified by this work, 12B1, has short, strongly
turn-promoting linker residues, with P residues on both sides of
the epitope.
The antigenicity of the chimeric viruses (i.e., the ability of the
viruses to bind to 2F5 or 4E10) was evaluated using direct
ELISAs, competitive ELISAs, and an MTT cell-killing assay. It
is worth noting that the ELISAs required considerable
optimization to overcome complications associated with the
extreme hydrophobicity of the MPER region (particularly for the
4E10 epitope) as well as of the antibodies (particularly 4E10).
Indeed, the CDR H3 of 4E10 is extraordinarily hydrophobic and
polyspecific [77,78], requiring optimal choices for the
preparation of the reagents and selection of solvents. The
4E10 peptide, in particular, was rendered soluble by the
inclusion of an α-helix-promoting lactam bridge between the K7
and D11 of the peptide, a series of solubilizing lysines at the C-
terminus, and dissolution in 10% acetic acid. The results
obtained from the different binding assays were highly
concordant. Overall, the binding assays revealed that the
chimeric virus with the longer linkers and greater percentage of
α-helix promoting residues displayed the more favorable
binding to 4E10.
Using a prime-boost approach for immunization, guinea pigs
were primed with chimeric viruses and boosted with chimeric
viruses and KLH-conjugated epitope peptides. The sera
generated from the guinea pigs were then tested for their ability
to neutralize HIV-1. Numerous sera elicited from a variety of
the chimeric viruses showed a notable breadth of their ability to
neutralize varied HIV pseudoviruses. It is worth noting,
however, that the neutralization was modest, predictably as
impacted by the choice of the MPER target, which has yet to
elicit high titer neutralizing responses in any recombinant
setting, and also by the fact that HRV does not replicate in
guinea pigs. In this regard, any neutralization of HIV elicited by
an MPER-based construct constitutes a notable achievement.
Remarkably, one chimeric virus, 12B1, generated an
exceedingly broad neutralization spectrum. Serum from this
chimera was able to neutralize 10 of 12 pseudovirus isolates.
Four other chimeras (the 2F5-presenting chimera, B1-16, and
the 4E10-presenting chimeras, 02A1, 02B2, and 22C1) were
able to elicit neutralizing antibodies against pseudoviruses of at
least three subtypes). Interestingly, 12B1 compared poorly with
the other chimeras, as measured by ELISAs and the MTT cell-
killing assay. These measures of antigenicity, while not
predictive of the best immunogens, nonetheless offer help in
generally guiding our efforts toward the isolation and
identification of the most valuable immunogens.
Given the evidence that a long CDR-H3 is essential for
neutralization by 2F5 [79,80] and 4E10 [26], it is conceivable
that 12B1 also elicited antibodies with long H3 loops and/or,
possibly elicited polyreactive antibodies as well, improving its
breadth in neutralizing HIV without improving its affinity to the
W670NWFDITN677 sequence [26]. Another possibility is that the
antibodies elicited were able to find an unusual angle of
approach to the epitope and that the ability to access the
epitope outweighed the importance of its affinity.
One advantage offered by the chimeric HRV system is that
presentation of foreign epitopes on the VP2 puff of its
neutralizing immunogenic site II allows for a number of
possibilities that are less likely to occur in the context of native
HIV. On one hand, with the freedom afforded by genetic
engineering, one can generate epitope presentations that are
more accessible. The value of this benefit was recently
demonstrated by the identification of the new MPER mAb,
10E8 [81]. With its epitope consisting of
N671WFDITNWLWYIR683, containing both the 4E10 and Z13e1
epitopes (though on different faces), this antibody binds with
greater accessibility and affinity to the MPER than do mAbs
2F5, 4E10, and Z13e1, resulting in greater neutralizing potency
against many HIV pseudoisolates. It could be that greater
immunogenicity could have been achieved with the HRV: HIV
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gp41 MPER chimeras had some of them included the Y681, I682,
and the critical R683. However, it is quite possible that the
inclusion of the additional Y681IR683 could have been deleterious
to the growth of chimeric viruses or caused misfolding of the
epitope within the context of HRV. One could deduce that
having an immunogen that presents crucial residues in an
accessible way could lead to the production of antibodies that
are predisposed to bind to somewhat less accessible residues
when they do become more exposed. On another hand, tight
homotypic bivalent binding across the two-fold axis of HRV [82]
suggests that presentation of foreign epitopes that are not
normally involved in tight bivalent binding by antibodies can
now elicit such tightly binding antibodies, setting the stage for
potential increases in antibody-binding affinity. While such high
affinity bivalent binding to the MPER of HIV appears to be rare
[83], genetic engineering (including the engineering of HRV
chimeras) has the potential to expand the neutralization
horizon (conceivably obviating the tendency for antibodies to
make polyreactive contacts in such cases [84]). Given that the
MPER itself is weakly immunogenic in native HIV-1 infection,
improving neutralizing responses against this highly conserved
region is a priority for the development of AIDS vaccines.
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